Back Hepatitis C

Hepatitis C

AASLD 2014: AbbVie 3D Cures Recurrent HCV in Most Liver Transplant Recipients Without Cirrhosis

AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis or cirrhosis, according to results from the CORAL-I study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston and published in the November 11 advance edition of the New England Journal of Medicine.

alt

AASLD 2014: DAAs Show Good Cure Rates and Liver Function Improvement for Transplant Recipients with Recurrent HCV

A variety of interferon-free regimens containing the direct-acting antivirals sofosbuvir (Sovaldi), simeprevir (Olysio), and daclatasvir (Daklinza) led to high sustained virological response rates, often improved liver function, and were generally safe and reasonably well-tolerated by liver transplant recipients with hepatitis C recurrence, one of the most difficult populations to treat, according to several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston.

alt

Harvoni Coformulation Approved in Europe for Hepatitis C Genotypes 1 & 4

Gilead Sciences' Harvoni, a once-daily fixed-dose coformulation containing the nucleotide HCV polymerase inhibitor sofosbuvir and the NS5A replication complex inhibitor ledipasvir, has been approved by the European Commission for the treatment of people with hepatitis C genotypes 1 and 4, the company announced this week.

alt

AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Post-Transplant HCV Recurrence

An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis or less-advanced liver cirrhosis, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston. Response rates fell for people with more severe cirrhosis and signs of liver decompensation, but still a majority were cured.

alt

AASLD 2014: Daclatasvir + Sofosbuvir Demonstrates Good Cure Rate for HCV Genotype 3 Patients

An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi) taken for 12 weeks produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus genotype 3 in the Phase 3 ALLY-3 trial, researchers reported last week at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. This regimen did not work as well, however, for people with liver cirrhosis.

alt

AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use

Regimens containing sofosbuvir (Sovaldi) -- including sofosbuvir plus simeprevir (Olysio) -- work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently in need of treatment at the dawn of the interferon-free era, according to a pair of presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Sofosbuvir plus ribavirin alone is highly effective for people with genotype 2.

alt

AASLD 2014: Sofosbuvir + GS-5816 for 12 Weeks Shows High Cure Rates, 8 Weeks Less Effective

A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to Phase 2 study findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration to 8 weeks resulted in lower efficacy for people with HCV genotypes 1 and 2, though genotype 3 patients still showed high response rates.

alt

AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection

AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most patients with HIV and hepatitis C virus (HCV) coinfection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.

alt

AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected

An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response rates for treatment-naive and treatment-experienced genotype 1 hepatitis C patients, including people with liver cirrhosis and HIV/HCV coinfection, according to research presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston and published simultaeously in The Lancet. However, pushing treatment duration with this combination plus sofosbuvir down to 4 or 6 weeks raised the risk of treatment failure.

alt